Optimal VMAT techniques for adjuvant breast radiotherapy (n)over-tilde initial results of cooperative study from two institutes

被引：0
|
作者：
Topczewska-Bruns, J. [1 ]
Kawa-Iwanicka, A. [2 ]
Pancewicz-Janczuk, B. [3 ]
Polaczek-Grelik, K. [2 ]
Kokoszka, A. [4 ]
Kisielewska-Birycka, M. [3 ]
Filipowski, T. [1 ]
机构：
[1] Comprehens Canc Ctr, Dept Radiotherapy, Bialystok, Poland
[2] 2 NU MED Canc Diag & Treatment Ctr, Dept Phys, Katowice, Poland
[3] Comprehens Canc Ctr, Dept Phys, Bialystok, Poland
[4] 2 NU MED Canc Diag & Treatment Ctr, Dept Radiotherapy, Katowice, Poland
来源：
RADIOTHERAPY AND ONCOLOGY | 2015年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1584
引用
收藏
页码：S867 / S867
页数：1
相关论文
共 35 条
  • [31] Adjuvant radiotherapy in postmenopausal high-risk patients with breast carcinoma given tamoxifen. Results of a randomized study [Die adjuvante strahlentherapie bei postmenopausalen risiko-patientinnen mit mammakarzinom, die tamoxifen erhalten. Ergebnisse einer randomisierten studie (Danisch Breast Cancer Cooperative Group DBCG 82c)]
    Feldmann H.J.
    Der Onkologe, 1999, 5 (7): : 644 - 645
  • [32] Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
    Hurvitz, Sara A.
    Bosserman, Linda D.
    Chan, David
    Hagenstad, Christopher T.
    Kass, Frederick C.
    Smith, Frederick P.
    Rodriguez, Gladys I.
    Childs, Barrett H.
    Slamon, Dennis J.
    SPRINGERPLUS, 2014, 3 : 1 - 9
  • [33] Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
    Decker, Thomas
    Soeling, Ulrike
    Hahn, Antje
    Maintz, Christoph
    Kurbacher, Christian Martin
    Vehling-Kaiser, Ursula
    Sent, Dagmar
    Klare, Peter
    Hagen, Volker
    Chiabudini, Marco
    Falkenstein, Julia
    Indorf, Martin
    Runkel, Eva
    Potthoff, Karin
    BMC CANCER, 2020, 20 (01)
  • [34] Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
    Thomas Decker
    Ulrike Söling
    Antje Hahn
    Christoph Maintz
    Christian Martin Kurbacher
    Ursula Vehling-Kaiser
    Dagmar Sent
    Peter Klare
    Volker Hagen
    Marco Chiabudini
    Julia Falkenstein
    Martin Indorf
    Eva Runkel
    Karin Potthoff
    BMC Cancer, 20
  • [35] Phase 2 Trial of Primary Systemic Therapy With Doxorubicin and Docetaxel Followed by Surgery, Radiotherapy, and Adjuvant Chemotherapy With Cyclophosphamide, Methotrexate, and 5-Fluorouracil Based on Clinical and Pathologic Response in Patients With Stage IIB to III Breast Cancer Long-Term Results From The University of Texas M. D. Anderson Cancer Center Study ID97-099
    Alvarez, Ricardo H.
    Booser, Daniel J.
    Cristofanilli, Massimo
    Sahin, Aysegul A.
    Strom, Eric A.
    Guerra, Laura
    Kau, Shu-Wan
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    CANCER, 2010, 116 (05) : 1210 - 1217
1234